← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2006Last known activity
Jan 7, 2025
Timeline
2000s
- Jan 1, 2005
SymBio Pharmaceuticals— Founded
Drugs by trial phase (9 distinct, 23 trials)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Nausea
- Neoplasms
- Neoplasms, Plasma Cell
- Postoperative Pain
- Preleukemia
- Syndrome
- Vomiting
Recent trials (32)
- NCT06761677Lead sponsorPhase 1/Phase 2Jan 7, 2025
- NCT05511779Lead sponsorPhase 2Oct 14, 2022
- NCT04706923Lead sponsorPhase 2Aug 16, 2021
- NCT04542252Study directorPhase 1Nov 9, 2020
- NCT04542252Lead sponsorPhase 1Nov 9, 2020
- NCT03900377Lead sponsorPhase 1/Phase 2Apr 1, 2019
- NCT03604679Lead sponsorPhase 1May 24, 2018
- NCT03604679Study directorPhase 1May 24, 2018
- NCT03372837Lead sponsorPhase 3Jan 15, 2018
- NCT03495167Lead sponsorPhase 1Oct 6, 2017
- NCT03495167Study directorPhase 1Oct 6, 2017
- NCT03005899Study directorPhase 3Nov 1, 2016
- NCT03005899Lead sponsorPhase 3Nov 1, 2016
- NCT02783547Study directorPhase 1Dec 1, 2015
- NCT02783547Lead sponsorPhase 1Dec 1, 2015
Details
- Founded
- Tokyo, JP Jan 1, 2005
- Last known activity
- Jan 7, 2025